Charles Pitman CFA
Stock Analyst at Barclays
(4.83)
# 435
Out of 5,108 analysts
239
Total ratings
73.6%
Success rate
17.9%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: BIM bioMérieux S.A. | Reiterated: Hold | €80.00 → €90.00 | €94.75 | -5.01% | 9 | Nov 3, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 730.00 → CHF 770.00 | CHF 672.40 | +14.52% | 36 | Oct 30, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Sell | €145.00 | €159.40 | -9.03% | 36 | Oct 29, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €150.00 → €160.00 | €150.35 | +6.42% | 23 | Oct 28, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €310.00 → €320.00 | €287.50 | +11.30% | 25 | Oct 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €240.00 → €250.00 | €224.20 | +11.51% | 20 | Sep 30, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Hold | CHF 70.00 → CHF 80.00 | CHF 79.75 | +0.31% | 13 | Sep 8, 2026 | |
| SWX: PPGN PolyPeptide Group AG | Reiterated: Hold | CHF 44.31 | CHF 40.50 | +9.41% | 8 | Sep 8, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €60.00 → €70.00 | €56.22 | +24.51% | 18 | Sep 8, 2026 | |
| BIT: DIA DiaSorin S.p.A. | Reiterated: Sell | €60.00 → €70.00 | €80.64 | -13.19% | 4 | Sep 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €48.00 → €50.00 | €53.05 | -5.75% | 16 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €13.50 → €12.50 | €11.28 | +10.82% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 75.00 | CHF 83.62 | -10.31% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $15.52 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $530.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $652 → $731 | $894.77 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $20 | $8.46 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $288.24 | n/a | 1 | Jan 13, 2022 |
bioMérieux S.A.
Nov 3, 2026
Reiterated: Hold
Price Target: €80.00 → €90.00
Current: €94.75
Upside: -5.01%
Lonza Group AG
Oct 30, 2026
Reiterated: Buy
Price Target: CHF 730.00 → CHF 770.00
Current: CHF 672.40
Upside: +14.52%
Ipsen S.A.
Oct 29, 2026
Reiterated: Sell
Price Target: €145.00
Current: €159.40
Upside: -9.03%
Merck KGaA
Oct 28, 2026
Reiterated: Hold
Price Target: €150.00 → €160.00
Current: €150.35
Upside: +6.42%
Sartorius Aktiengesellschaft
Oct 23, 2026
Reiterated: Buy
Price Target: €310.00 → €320.00
Current: €287.50
Upside: +11.30%
Sartorius Stedim Biotech S.A.
Sep 30, 2026
Reiterated: Buy
Price Target: €240.00 → €250.00
Current: €224.20
Upside: +11.51%
Bachem Holding AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 70.00 → CHF 80.00
Current: CHF 79.75
Upside: +0.31%
PolyPeptide Group AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 44.31
Current: CHF 40.50
Upside: +9.41%
Bayer Aktiengesellschaft
Sep 8, 2026
Reiterated: Buy
Price Target: €60.00 → €70.00
Current: €56.22
Upside: +24.51%
DiaSorin S.p.A.
Sep 7, 2026
Reiterated: Sell
Price Target: €60.00 → €70.00
Current: €80.64
Upside: -13.19%
Jul 30, 2026
Reiterated: Hold
Price Target: €48.00 → €50.00
Current: €53.05
Upside: -5.75%
Apr 22, 2026
Reiterated: Buy
Price Target: €13.50 → €12.50
Current: €11.28
Upside: +10.82%
Mar 11, 2026
Reiterated: Hold
Price Target: CHF 75.00
Current: CHF 83.62
Upside: -10.31%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $15.52
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $530.00
Upside: -
Apr 28, 2025
Reiterated: Buy
Price Target: $652 → $731
Current: $894.77
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $20
Current: $8.46
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $288.24
Upside: n/a